Bladder Carcinoma

  • Declan O’RourkeEmail author


Bladder Carcinoma: this chapter outlines the incidence, risk factors, clinical presentation, investigations, treatments and prognosis of cancer at this anatomical site. These features are correlated with the core data that are required to make corresponding histopathology reports of a consistently high quality, available in an appropriate timeframe, and clinically relevant to patient management and prognosis. Summary details of the common cancers given at this site include: gross description, histological types, tumour grade/differentiation, extent of local tumour spread, lymphovascular invasion, lymph node involvement, and the status of excision margins. Current WHO Classifications of Malignant Tumours and TNM8 are referenced. Notes are provided on other associated pathology, contemporary use of immunohistochemistry, updates on the role of evolving molecular tests, and the use of these ancillary techniques as biomarkers in diagnosis, and prediction of prognosis and treatment response. A summary is given of the more common non-carcinoma malignancies that are encountered at this site in diagnostic practice.


Urothelial carcinoma TNM8 Carcinoma in situ WHO grading Immunohistochemistry 


  1. Al Bashir S, Yilmaz A, Gotto G, Trpkov K. Long term outcome of primary urothelial papilloma: a single institution cohort. Pathology. 2014;46:37.CrossRefGoogle Scholar
  2. Allen DC, Cameron RI. Histopathology specimens: clinical, pathological and laboratory aspects. 3rd ed. London: Springer; 2017.CrossRefGoogle Scholar
  3. Bertz S, Denzinger S, Otto W, Wieland WF, Stoehr R, Hofstaedter F, Hartmann A. Substaging by estimating the size of invasive tumour can improve risk stratification in pT1 bladder cancer—evaluation of a large hospital-based single-centre series. Histopathology. 2011;59:722–32.CrossRefGoogle Scholar
  4. Bovio IM, Al-Quran SZ, Rosser CJ, Algood CB, Drew PA, Allan RW. Smoothelin immunohistochemistry is a useful adjunct for assessing muscularis propria invasion in bladder carcinoma. Histopathology. 2010;56:951–6.CrossRefGoogle Scholar
  5. Chandra A, Griffiths D, McWilliam LJ. Best Practice: gross examination and sampling of surgical specimens from the urinary bladder. J Clin Pathol. 2010;63:475–9.CrossRefGoogle Scholar
  6. Cox R, Epstein JI. Large nested variant of urothelial carcinoma: 23 cases mimicking von Brunn nests and inverted growth pattern of noninvasive papillary urothelial carcinoma. Am J Surg Pathol. 2011;35:1337.CrossRefGoogle Scholar
  7. Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder consensus conference committee. Am J Surg Pathol. 1998;22:1435.CrossRefGoogle Scholar
  8. Fox MD, Li X, Zhang M, Kamat AM, Siefker-Radtke A, Zhang L, Dinney CP, Czerniak B, Guo CC, Xiao L, Zhang M, Zhang L. Plasmacytoid urothelial carcinoma of the urinary bladder: a clinicopathologic and immunohistochemical analysis of 49 cases. Am J Clin Pathol. 2017;147:500–6.CrossRefGoogle Scholar
  9. Harik LR, Merino M, Coindre J-M, Amin MB, Pedeutour F, Weiss SW. Pseudosarcomatous myofibroblastic proliferations of the bladder. A clinicopathological study of 42 cases. Am J Surg Pathol. 2006;30:787–94.CrossRefGoogle Scholar
  10. Holmäng S, Johansson SL. The nested variant of transitional cell carcinoma-a rare neoplasm with poor prognosis. Scand J Urol Nephrol. 2001;35:102.CrossRefGoogle Scholar
  11. Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO classification of tumours of the urinary system and male genital organs-part B: prostate and bladder tumours. Eur Urol. 2016;70:106–19.CrossRefGoogle Scholar
  12. Kumar N, Khosla D, Kumar R, et al. Urachal carcinoma: clinicopathological features, treatment and outcome. J Cancer Res Ther. 2014;10:571.PubMedGoogle Scholar
  13. Lagwinski N, Thomas A, Stephenson AJ, et al. Squamous cell carcinoma of the bladder: a clinicopathologic analysis of 45 cases. Am J Surg Pathol. 2007;31:1777.CrossRefGoogle Scholar
  14. Lee TK, Chaux A, Karram S, et al. Papillary urothelial neoplasm of low malignant potential of the urinary bladder: clinicopathologic and outcome analysis from a single academic center. Hum Pathol. 2011;42:1799.CrossRefGoogle Scholar
  15. Lopez-Beltran A, Algaba F, Berney DM, Boccon – Gibod L, Camparo P, Griffiths D, Mikuz G, Montironi R, Varma M, Egevad L. Handling and reporting of transurethral resection specimens of the bladder in Europe: a web-based survey by the European Network of Uropathology (ENUP). Histopathology. 2011;58:579–85.CrossRefGoogle Scholar
  16. Magers MJ, Lopez-Beltran A, Montironi R, Williamson SR, Kaimakliotis HZ, Cheng L. Staging of bladder cancer. Histopathology. 2019;74:112–34.CrossRefGoogle Scholar
  17. McKenney JK. Precursor lesions of the urinary bladder. Histopathology. 2019;74:68–76.CrossRefGoogle Scholar
  18. Miyamoto H, Miller JS, Fajardo DA, et al. Non-invasive papillary urothelial neoplasms: the 2004 WHO/ISUP classification system. Pathol Int. 2010;60:1.CrossRefGoogle Scholar
  19. Moch H, Humphrey PA, Ulbright TM, Reuter VE. WHO classification of tumours of the urinary system and male genital organs. Geneva: WHO Press; 2016.Google Scholar
  20. Montironi R, Lopez-Beltran A, Scarpelli M, , Mazzucchelli R, Cheng L. Morphological classification and definition of benign, preneoplastic and non-invasive neoplastic lesions of the urinary bladder. Histopathology 2008;53:621–633.CrossRefGoogle Scholar
  21. Mostofi FK, Sobin LH, Torloni H, editors. Histological typing of urinary bladder tumors. Geneva: WHO; 1973.Google Scholar
  22. Picozzi S, Casellato S, Bozzini G, et al. Inverted papilloma of the bladder: a review and an analysis of the recent literature of 365 patients. Urol Oncol. 2013;31:1584.CrossRefGoogle Scholar
  23. Pons F, Orsola A, Morote J, Bellmunt J. Variant forms of bladder cancer: basic considerations on treatment approaches. Curr Oncol Rep. 2011;13:216.CrossRefGoogle Scholar
  24. Shanks JH, Iczkowski KA. Divergent differentiation in urothelial carcinoma and other bladder cancer subtypes with selected minics. Histopathology. 2009;54:885–900.CrossRefGoogle Scholar
  25. The Royal College of Pathologists. Standards and datasets for reporting cancers. Dataset for tumours of the urinary collecting system (renal pelvis, ureter, urinary bladder and urethra) (2nd ed) 2013.
  26. Wang J, Wang FW. The natural history, treatment pattern, and outcomes of patients with micropapillary bladder carcinoma. Am J Clin Oncol. 2015;38:472.CrossRefGoogle Scholar
  27. Wasco MJ, Daignault S, Zhang Y, et al. Urothelial carcinoma with divergent histologic differentiation (mixed histologic features) predicts the presence of locally advanced bladder cancer when detected at transurethral resection. Urology. 2007;70:69.CrossRefGoogle Scholar
  28. Westfall DE, Folpe AL, Paner GP, Oliva E, Goldstein L, Alsabeh R, Gown AM, Amin MB. Utility of a comprehensive immunohistochemical panel in the differential diagnosis of spindle cell lesions of the urinary bladder. Am J Surg Pathol. 2009;33:99–105.CrossRefGoogle Scholar
  29. Williamson SR, Lopez-Beltran A, Montironi R, Cheng L. Glandular lesions of the urinary bladder: clinical significance and differential diagnosis. Histopathology. 2011a;58:811–34.CrossRefGoogle Scholar
  30. Williamson SR, Zhang S, Lopez-Beltran A, Shah RB, Montironi R, Tan PH, Wang M, Baldridge LA, MacLennan GT, Cheng L. Lymphoepithelioma-like carcinoma of the urinary bladder: clinicopathologic, immunohistochemical, and molecular features. Am J Surg Pathol. 2011b;35:474–83.CrossRefGoogle Scholar
  31. Wright JL, Black PC, Brown GA, Porter MP, Kamat AM, Dinney CP, Lin DW. Differences in survival among patients with sarcomatoid carcinoma, carcinosarcoma and urothelial carcinoma of the bladder. J Urol. 2007;178:2302–6.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Institute of PathologyRoyal Victoria HospitalBelfastUK

Personalised recommendations